Skip to main content
Clinical Trials/EUCTR2019-000099-41-GB
EUCTR2019-000099-41-GB
Active, not recruiting
Phase 1

Motor Neurone Disease Systematic Multi-arm Adaptive Randomised Trial (MND-SMART) - MND-SMART

niversity of Edinburgh0 sites750 target enrollmentJuly 25, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Motor Neurone Disease
Sponsor
niversity of Edinburgh
Enrollment
750
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 25, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity of Edinburgh

Eligibility Criteria

Inclusion Criteria

  • ·Confirmed diagnosis of MND (including the following subtypes: ALS by El Escorial Criteria (possible, probable, and definite), Primary Lateral Sclerosis, and Progressive Muscular Atrophy)
  • ·Women of childbearing potential according to CTFG guidelines (http://www.hma.eu/fileadmin/dateien/Human\_Medicines/01\-About\_HMA/Working\_Groups/CTFG/2014\_09\_HMA\_CTFG\_Contraception.pdf) must have a negative pregnancy test within 7 days prior to the baseline visit
  • ·Women of childbearing potential and fertile men (according to CTFG guidelines) must be using an appropriate method of contraception to avoid any unlikely teratogenic effects of the selected drugs from time of consent, to 4 weeks after treatment inclusive
  • ·Willing and able to comply with the trial protocol and ability to understand and complete questionnaires
  • ·Written informed consent (this can be signed by a proxy in the case of limb dysfunction)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 375
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • Patients diagnosed with Fronto\-temporal Dementia (FTD\-MND) or any other significant psychiatric disorder that prevents informed consent being given.
  • Patients in the manic phase of bipolar disorder.
  • Alcoholism (self\-reported)
  • Active suicide ideation assessed using the Columbia\-Suicide Severity Rating Scale
  • On concurrent investigational medication (including biological therapy)
  • Known hypersensitivity, including hereditary fructose intolerance, or adverse reaction to the active substances and their excipients or any past medical history contraindicating use of any of the IMPs
  • Pregnancy or breast\-feeding females
  • If ALT, ALP, bilirubin or GGT \>3 times the upper limit of normal.
  • If creatinine clearance (creatinine clearance or eGFR) \<30 ml/min.
  • If Serum free T4 \>25pmol/l or TSH \<0\.2mU/l

Outcomes

Primary Outcomes

Not specified

Similar Trials